| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_399d426408ce1e752b8d3915985741a1 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-78 |
| filingDate |
2013-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81f8c7903bf41c8388069812777f3e2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80ce166298e54a020ca1995e2d1ee7bd |
| publicationDate |
2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014185136-A |
| titleOfInvention |
Process for producing danidazole constituent optical isomers |
| abstract |
An asymmetric synthesis of constitutive optically active substances of dranidazole, and the pharmacological and physicochemical characteristics of each optically active substance are clarified. A compound represented by the structural formula (1) In which trimethylsilyl-2-nitroimidazole and a specific polyhydric alcohol derivative are condensed in the presence of a catalyst, and then deprotected ((2S3R) -3- (2-nitroimidazol-1-ylmethoxy). ) Butane-1,2,4-triol). [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110105371-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110105371-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014185135-A |
| priorityDate |
2013-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |